Wall Street brokerages expect that AmerisourceBergen Corp. (NYSE:ABC) will post sales of $45.31 billion for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for AmerisourceBergen’s earnings. The highest sales estimate is $45.46 billion and the lowest is $45.17 billion. AmerisourceBergen reported sales of $43.30 billion in the same quarter last year, which indicates a positive year-over-year growth rate of 4.6%. The firm is scheduled to issue its next earnings results on Tuesday, November 5th.

On average, analysts expect that AmerisourceBergen will report full year sales of $178.72 billion for the current financial year, with estimates ranging from $176.54 billion to $179.41 billion. For the next fiscal year, analysts expect that the business will post sales of $187.64 billion, with estimates ranging from $186.59 billion to $188.55 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for AmerisourceBergen.

AmerisourceBergen (NYSE:ABC) last announced its quarterly earnings data on Thursday, August 1st. The company reported $1.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.62 by $0.14. The firm had revenue of $45.24 billion during the quarter, compared to analysts’ expectations of $45.15 billion. AmerisourceBergen had a return on equity of 47.88% and a net margin of 0.54%. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.54 EPS.

Several equities analysts have recently issued reports on the company. TheStreet upgraded AmerisourceBergen from a “c+” rating to a “b” rating in a research note on Thursday, August 1st. ValuEngine downgraded AmerisourceBergen from a “hold” rating to a “sell” rating in a report on Tuesday, August 6th. Zacks Investment Research raised AmerisourceBergen from a “hold” rating to a “buy” rating and set a $89.00 target price on the stock in a report on Wednesday, June 12th. Finally, Argus cut their target price on AmerisourceBergen from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, June 3rd. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. AmerisourceBergen currently has an average rating of “Hold” and a consensus target price of $88.00.

Shares of ABC traded down $0.77 during midday trading on Friday, hitting $85.55. The company’s stock had a trading volume of 894,034 shares, compared to its average volume of 1,424,768. AmerisourceBergen has a one year low of $69.36 and a one year high of $94.85. The company’s fifty day simple moving average is $87.59 and its two-hundred day simple moving average is $82.13. The company has a quick ratio of 0.56, a current ratio of 0.95 and a debt-to-equity ratio of 1.40. The stock has a market capitalization of $18.44 billion, a price-to-earnings ratio of 13.18, a price-to-earnings-growth ratio of 1.57 and a beta of 0.97.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Monday, August 19th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 1.87%. The ex-dividend date is Friday, August 16th. AmerisourceBergen’s dividend payout ratio (DPR) is currently 24.65%.

In other AmerisourceBergen news, insider John G. Chou sold 13,997 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $89.58, for a total transaction of $1,253,851.26. Following the completion of the sale, the insider now directly owns 65,782 shares of the company’s stock, valued at approximately $5,892,751.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Robert P. Mauch sold 24,767 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $81.16, for a total value of $2,010,089.72. Following the sale, the executive vice president now directly owns 43,286 shares of the company’s stock, valued at $3,513,091.76. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 185,336 shares of company stock worth $16,014,325. 27.80% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in AmerisourceBergen by 16.8% during the 2nd quarter. Vanguard Group Inc. now owns 18,910,594 shares of the company’s stock worth $1,612,318,000 after purchasing an additional 2,719,868 shares in the last quarter. BlackRock Inc. grew its holdings in shares of AmerisourceBergen by 1.1% in the second quarter. BlackRock Inc. now owns 12,325,863 shares of the company’s stock valued at $1,050,903,000 after acquiring an additional 136,458 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of AmerisourceBergen by 9.7% in the second quarter. Victory Capital Management Inc. now owns 2,769,023 shares of the company’s stock valued at $236,087,000 after acquiring an additional 245,394 shares in the last quarter. Northern Trust Corp grew its holdings in shares of AmerisourceBergen by 3.3% in the second quarter. Northern Trust Corp now owns 2,514,818 shares of the company’s stock valued at $214,414,000 after acquiring an additional 81,207 shares in the last quarter. Finally, Beutel Goodman & Co Ltd. grew its holdings in shares of AmerisourceBergen by 2.5% in the second quarter. Beutel Goodman & Co Ltd. now owns 2,355,121 shares of the company’s stock valued at $153,329,000 after acquiring an additional 57,604 shares in the last quarter. 65.03% of the stock is owned by hedge funds and other institutional investors.

AmerisourceBergen Company Profile

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.

Further Reading: If I purchase shares through a brokerage account, am I the holder of record?

Get a free copy of the Zacks research report on AmerisourceBergen (ABC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AmerisourceBergen (NYSE:ABC)

Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.